Most patients with advanced penile cancer will have relapsed disease after cisplatin-based combination chemotherapy. Unfortunately, these patients have dismal outcomes with salvage chemotherapy, surgery, or radiation. In this review we will discuss the available chemotherapy and targeted therapies for salvage second line systemic treatment for patients with penile cancer. We will also summarize the ongoing interventional clinical trials using immune and human papilloma virus-based therapies.
Second line salvage systemic therapy for advanced penile cancer / Chahoud, J.; Tamil, M.; Necchi, A.. - In: UROLOGIC ONCOLOGY. - ISSN 1078-1439. - 40:6(2022), pp. 229-234. [10.1016/j.urolonc.2020.08.001]
Second line salvage systemic therapy for advanced penile cancer
Necchi A.
Ultimo
2022-01-01
Abstract
Most patients with advanced penile cancer will have relapsed disease after cisplatin-based combination chemotherapy. Unfortunately, these patients have dismal outcomes with salvage chemotherapy, surgery, or radiation. In this review we will discuss the available chemotherapy and targeted therapies for salvage second line systemic treatment for patients with penile cancer. We will also summarize the ongoing interventional clinical trials using immune and human papilloma virus-based therapies.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
